Facebook Live: CAR T-Cell Therapy and Lymphoma
10/25/17: Caron Jacobson, MD, Medical Director of the Immune Effector Cell Therapy program at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), discussed the recent approval of chimeric antigen receptor (CAR) T-cell therapy for certain patients with non-Hodgkin lymphoma in a Facebook Live broadcast.
▶︎
Update on CAR T-Cell Therapy | Lymphoma Research Foundation Webinars
▶︎
Diffuse Large B-Cell Lymphoma (DLBCL) EXPLAINED
▶︎
CAR T-cell Therapy: The Good, The Bad and The Long-Term 2022
▶︎
Doctors break down every stage of lymphoma | Cancer: Explained | Macmillan Cancer Support
▶︎
CAR T at UCLA: Driving the Progress of Engineered Cell Therapy | Sarah Larson, MD | UCLAMDChat
▶︎
Follicular Lymphoma: Update on Upfront and Maintenance Therapy
▶︎
CAR T-Cell Therapy | FAQ with Dr. Patrick Brown
▶︎
Improving CAR-T Cell Therapies (Immunotherapy Documentary Part III)
▶︎
Non-Hodgkin Lymphoma: First Symptoms, Diagnosis & the LATEST Treatments | The Patient Story
▶︎
Relapsed and Refractory Diffuse Large B-Cell Lymphoma
▶︎
What’s Next in CAR T Cell Therapy with Dr. Michel Sadelain
▶︎
Before you Start or Refuse Cancer Therapy- WATCH THIS!
▶︎
Lymphoma Focus Day Low grade non Hodgkin lymphoma Rob Lown
▶︎
CAR T and Bispecific Antibody Therapies in Multiple Myeloma
▶︎
What diffuse large B-cell lymphoma patients should receive therapy different from R-CHOP?
▶︎
Tumour immunology and immunotherapy
▶︎
Chronic Lymphocytic Leukemia -- Cancer Guide
▶︎
Therapeutic T cell engineering: CD19 CAR therapy and beyond
▶︎
Understanding CAR T-Cell Therapy for Lymphoma with Andrew Zelenetz, MD, PhD
▶︎